1. Binding of lactoferrin to the surface of low-density lipoproteins modified by myeloperoxidase prevents intracellular cholesterol accumulation by human blood monocytes
- Author
-
Vasilyev, V.B., Sokolov, A.V., Kostevich, V.A., Elizarova, A.Yu., Gorbunov, N.P., and Panasenko, O.M.
- Subjects
Cholesterol -- Physiological aspects ,Blood lipoproteins -- Physiological aspects ,Protein binding -- Observations ,Proteolipids -- Physiological aspects ,Peroxidase -- Physiological aspects ,Lipoproteins -- Physiological aspects ,Lactoferrins -- Physiological aspects ,Biological sciences - Abstract
Myeloperoxidase (MPO) is a unique heme-containing peroxidase that can catalyze the formation of hypochlorous acid (HOCl). The strong interaction of MPO with low-density lipoproteins (LDL) promotes proatherogenic modification of LDL by HOCl. The MPO-modified LDL (Mox-LDL) accumulate in macrophages, resulting in the formation of foam cells, which is the pathognomonic symptom of atherosclerosis. A promising approach to prophylaxis and atherosclerosis therapy is searching for remedies that prevent the modification or accumulation of LDL in macrophages. Lactoferrin (LF) has several application points in obesity pathogenesis. We aimed to study LF binding to Mox-LDL and their accumulation in monocytes transformed into macrophages. Using surface plasmon resonance and ELISA techniques, we observed no LF interaction with intact LDL, whereas Mox-LDL strongly interacted with LF. The affinity of Mox-LDL to LF increased with the degree of oxidative modification of LDL. Moreover, an excess of MPO did not prevent interaction of Mox-LDL with LF. LF inhibits accumulation of cholesterol in macrophages exposed to Mox-LDL. The results obtained reinforce the notion of LF potency as a remedy against atherosclerosis. Key words: lactoferrin, low-density lipoproteins, myeloperoxidase, halogenative stress, cholesterol, atherosclerosis. La myeloperoxydase (MPO) est une peroxydase unique a heme qui peut catalyser la formation d'acide hypochloreux (HOCl). La forte interaction entre la MPO et les proteines de faible densite (LDL) favorise la modification proatherogene des LDL par le HOCl. Les LDL modifiees par la MPO (Mox-LDL) s'accumulent dans les macrophages donnant lieu a la formation de cellules spumeuses, ce qui est le symptome pathognomonique de l'atherosclerose. Une approche prometteuse de prophylaxie et de therapie de l'atherosclerose consiste a rechercher des remedes qui previennent la modification ou l'accumulation des LDL dans les macrophages. La lactoferrine (LF) offre plusieurs points d'intervention dans la pathogenese de l'obesite. Les auteurs avaient pour objectif d'etudier la liaison de la LF aux Mox-LDL et leur accumulation dans les monocytes transformes en macrophages. Ils n'ont observe aucune interaction entre la LF et les LDL intacts par resonance plasmonique de surface et ELISA, contrairement aux Mox-LDL qui interagissaient fortement avec la LF. L'affinite des Mox-LDL pour la LF augmentait avec le degre de modification oxydative des LDL. Qui plus est, un exces de MPO ne prevenait pas l'interaction entre les Mox-LDL et la LF. La LF inhibe l'accumulation de cholesterol dans les macrophages exposes aux Mox-LDL. Les resultats obtenus renforcent la notion de la capacite de la LF d'agir comme remede contre l'atherosclerose. [Traduit par la Redaction] Mots-cles : lactoferrine, lipoproteines de faible densite, myeloperoxydase, stress halogenant, cholesterol, atherosclerose., Introduction The role of immunologic factors in atherogenesis has been studied extensively in recent years. Atherosclerosis is now regarded as chronic immune inflammation. Meanwhile, the key role of excessive amounts [...]
- Published
- 2021
- Full Text
- View/download PDF